News
Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...
When somebody's coming in that has a known diagnosis of atopic dermatitis or eczema and things are really revved up still, if ...
In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.
The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...
12d
Health on MSNSpongiotic Dermatitis: Symptoms, Causes, and How To Treat ItSpongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with ...
1d
Clinical Trials Arena on MSNLEO Pharma reports results from interim analysis of Phase IIIb atopic dermatitis trialLEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
The Many Ways to Measure the Severity of Atopic Dermatitis — Validated physician-reported tools are often complicated, but patient-based measures are easy and informative ...
Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...
Eczema Types: Atopic Dermatitis Diagnosis and Treatment -- A Guide for Patients – An American Academy of Dermatology Association Reading Room selection June 19, 2025 • 9 min read ...
Certain pain-related pruritus descriptors may independently predict mental health outcomes, sleep disturbance, and QOL reduction in patients with AD.
Nektar Therapeutics’ biologic drug rezpegaldesleukin takes a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results